How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers.
LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications.
Many have seen the rise of GLP-1 drugs as a threat to the medical device industry.
Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea.
Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.
Persons:
Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom
Organizations:
Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance
Locations:
GLP, U.S, DaVita, ResMed